Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
As previously disclosed, on May 8, 2025, ProKidney Corp. (the "Company"), through its wholly owned subsidiary, ProKidne...
Chamath Palihapitiya is back with another SPAC. This time he's telling retail investors to stay away. Here's why.
Chamath Palihapitiya is back with a new SPAC. Many investors will remember past SPACs the investor was involved with and the po...
ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.15) by ...
https://www.zacks.com/stock/news/2589077/prokidney-cp-prok-upgraded-to-strong-buy-what-does-it-mean-for-the-stock
UBS analyst Eliana Merle maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price target from $4 to $8.
FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD ...
